New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on May 7, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Former 10% shareholder Lilly Endowment Inc has trimmed its stake in Eli Lilly & Co., offloading 15,828 shares of the pharmaceutical giant. The transaction, valued at $15,754,461, highlights a significant move by one of the company’s prominent legacy investors, signaling a noteworthy shift in its long-standing holdings of Eli Lilly stock.
Recent Updates on LLY stock
Eli Lilly’s shares reacted to a series of pipeline updates as multiple trials advanced or completed across obesity, diabetes, renal, and autoimmune programs. Investors focused on the completed Phase 2 obesity combo trial with Regeneron’s mibavademab plus tirzepatide, which tightens the timeline to weight‑loss data that could extend tirzepatide’s life cycle and defend Lilly’s lead in a rapidly growing market.
Sentiment was also shaped by completion of early renal pharmacokinetic studies for LY3537031 and LY3537982 and an active Phase 1 trial for autoimmune drug LY4298445, reducing dosing and safety uncertainty in kidney‑impaired patients and signaling diversification beyond obesity. A finished Phase 3 trial of oral orforglipron versus insulin glargine added expectations for future GLP‑1 data that could support a shift from injectables to oral therapies, underpinning valuation and driving analysts to reassess assumptions rather than broader market factors.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
The score is driven primarily by outstanding financial performance and a strongly positive earnings call with raised guidance. Offsetting factors are a premium valuation and mixed/neutral technical signals, with leverage and pricing pressure remaining key risks to monitor.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
YTD Price Performance: -8.00%
Average Trading Volume: 3,092,283
Technical Sentiment Signal: Strong Buy
Current Market Cap: $929.5B